Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug;60(8):1127-35.
doi: 10.1007/s00262-011-0985-7. Epub 2011 Apr 9.

Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies

Yeranddy A Alpizar  1 , Benjamin Chain, Mary K Collins, John Greenwood, David Katz, Hans J Stauss, N Avrion Mitchison
Affiliations
Review

Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies

Yeranddy A Alpizar et al. Cancer Immunol Immunother. 2011 Aug.

Abstract

Although cancer immunology has made vigorous progress over the last decade, its future remains uncertain. Tumors have clearly proved subject to immune surveillance, leading to antigenic editing, and means of activating both T and B arms of the immune system have been devised. Therapeutic vaccination and monoclonal antibody therapy have so far proved disappointing, because tumors prove adept at evasion from immune control. Dual targeting could well counteract evasion, provided that the two targets are independent and are attacked simultaneously. This stage has nearly but not quite been reached in several forms of immunotherapy, particularly of B-cell cancers, although such treatment also carries hazards.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Progress in cancer immunotherapy delayed by evasion
See this image and copyright information in PMC

References

    1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. doi: 10.1038/35074122. - DOI - PubMed
    1. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–907. doi: 10.1038/nature06309. - DOI - PubMed
    1. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Hakansson L. Improving the efficacy of cancer immunotherapy. Eur J Cancer. 2009;45:1424–1431. doi: 10.1016/j.ejca.2008.12.017. - DOI - PubMed
    1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67. doi: 10.1016/S0140-6736(07)61050-2. - DOI - PubMed
    1. Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst JM, Melief CJ, Fleuren GJ, Kenter GG, van der Burg SH (2010) The detection of circulating Human Papillomavirus (HPV)-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer - PubMed

LinkOut - more resources